Pathology review in an early prostate cancer detection program: Results from the american cancer society‐national prostate cancer detection project

Mostofi, F. K.; Murphy, Gerald P.; Mettlin, Curtis; Sesterhenn, Isabell A.; Batsakis, John G.; Khaliq, Sehar; Nadimpalli, Venkat; Tahan, Steven R.; Siders, Douglas B.; Kollin, Jozef

doi:10.1002/pros.2990270103

Cited by 12 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the end of the study, histopathological classification, biochemical determinations, and clinical stage of the samples were revealed and correlated with lipid analyses. For each type of pathological tissue the clinical state of patients and also the criteria for classification of samples (benign or neoplastic) were evaluated following international scores such as those recommended by the American Joint Committee on Cancer Staging, World Health Organization, or Gleason scale [6][7][8]. Presence and localization of metastases were explored by specific medical studies such as magnetic resonance, X-ray computed tomography, and radioisotopic densitography.…”

Section: Patients and Tissue Samplesmentioning

confidence: 99%

A Reliable Biomarker Derived from Plasmalogens to Evaluate Malignancy and Metastatic Capacity of Human Cancers

Smith

Lespi

Luca

et al. 2007

Lipids

View full text Add to dashboard Cite

Antigen tumor markers employed in monitoring therapeutical approaches are limited by their specificity (Sp) and sensitivity (Se). The aim of this study was to investigate the suitability of a lipid tumor marker derived from ether-linked phospholipids and to compare it with others usually assayed in clinical practice. Complex lipids from normal and pathological breast, lung, and prostate tissue were isolated and analyzed by TLC and c-GLC methods. Results were compared as pooled samples, or by means of the averaged percent changes with respect to the composition observed in the normal tissue of the same patient. Sp, Se, negative-predictive (NPV) and positive- predictive values (PPV) were established for conventional markers and for the proposed lipid-derived marker. Results demonstrated that the content of monoenoic fatty acyl chains was significantly increased in total lipids, phosphatidylethanolamine, and especially in ethanolamine-containing ether lipids of neoplastic tissues with respect to their corresponding normal ones. Major changes were observed in the plasmalogen sub-fraction where the ratio monoenoic/saturated fatty acids can distinguish with high Se normal tissues from either benign or neoplastic tissues from breast, lung, or prostate lesions. Analyses of fatty acyl chains from ethanolamine-containing plasmalogens provided a reliable tumor marker that correlated with high Se and linearity with metastases spreading. This fact may be useful in prognosis of the most frequently observed human cancers.

show abstract

Section: Patients and Tissue Samplesmentioning

confidence: 99%

A Reliable Biomarker Derived from Plasmalogens to Evaluate Malignancy and Metastatic Capacity of Human Cancers

Smith

Lespi

Luca

et al. 2007

Lipids

View full text Add to dashboard Cite

show abstract

“…According to our treatment selection categories, the patients in this study were characterized by low stage, low or intermediate grade disease, and favorable pretreatment PSA values. These criteria exemplify the improvement in prognostic parameters observed when otherwise healthy American men older than 50 years are screened for prostate carcinoma with PSA, digital rectal examination, and transrectal ultrasound 32‐34…”

mentioning

confidence: 99%

Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

Ragde

Blasko

Grimm

et al. 1997

Cancer

247

View full text Add to dashboard Cite

William Cavanagh, B.S. 3 Posttherapy evaluation included clinical, biochemical (PSA), and pathologic (repeat needle biopsy) studies. No patient was surgically staged, and none received andro-1 Pacific Northwest Cancer Foundation/Northgen deprivation therapy. Morbidity was graded according to the Radiation Therapy west Hospital, Seattle, Washington.Oncology Group grading scale. Statistical appraisal was performed by the Kaplan-2 Department of Urology, University of WashMeier method. PSA failure was defined in two ways: (1) PSA progression, i.e., 2 ington, Seattle, Washington.consecutive increases from a nadir value; and (2) failure to attain an arbitrary serum PSA value of 1.0 or 0.5 ng/mL at last follow-up. 3 Department of Radiation Oncology, University RESULTS. The overall 7-year survival was 77%; there were no deaths from prostate of Washington, Seattle, Washington.carcinoma in this cohort. The 7-year actuarial PSA progression free outcome was 4 Northwest Tumor Institute, Seattle, Washing-89%, and the PSA°1.0 ng/mL outcome was 87%. When PSA°0.5 ng/mL was ton.selected as an outcome end point, and PSA values in this series of radiation-treated 5 Pathology Associates Inc., Spokane, Washingpatients were compared with PSA values proposed to indicate disease free survival ton.after radical prostatectomy (PSA°0.3-°0.6 ng/mL), the 7-year actuarial disease free survival was 79%. Morbidity was minimal except in patients who had preimplant or postimplant transurethral prostate resection. CONCLUSIONS.Outpatient-based iodine-125 prostate brachytherapy for prostate carcinoma classified as T1 or T2 resulted in biochemical outcomes comparable to end points resulting from radical prostatectomy and external beam radiation.

show abstract

“…Cancer detection rates across the five annual examinations averaged 2.0%, with a high of 2.7% yielded by the first examination. Earlier reports from the ACS‐NPCDP and other studies have provided detailed assessments of the comparative sensitivity, specificity, and predictive value of PSA level, transrectal ultrasound, and digital rectal examination in the early detection of prostate cancer, and those results are not included in this report 4,5,11–13 …”

Section: Resultsmentioning

confidence: 99%

“…The principal study outcome was the diagnosis of prostate cancer. Slides for all patients diagnosed with cancer were reviewed by the ACS‐NPCDP review pathologist at the Armed Forces Institute of Pathology 5 . Classification of clinical stage was based originally on the Whit‐more paradigm, but for the purpose of comparison with data from the NCDB, cancers were assigned to American Joint Committee on Cancer (AJCC) pathologic stages I through IV 6,7 …”

Section: Introductionmentioning

confidence: 99%

The American Cancer Society National Prostate Cancer Detection Project and National patterns of prostate cancer detection and treatment

Mettlin

1997

CA: A Cancer Journal for Clinicians

Self Cite

View full text Add to dashboard Cite

and transrectal ultrasound were emerging technologies that had been investigated only in men already diagnosed with the disease. These new methods, of unknown potential for early detection, were combined with the previously studied digital rectal examination in a coordinated, multimodality intervention strategy.To demonstrate the range of settings in which advancing early detection of prostate cancer might be possible, the ACS-NPCDP involved a multidisciplinary group of investigators from different medical facilities, including community hospitals, university medical centers, cancer centers, and private medical practices. An annual examination protocol was established to replicate periodic testing, and healthy men at risk of prostate cancer were recruited to participate for 5 years.Although the ACS-NPCDP was established as a demonstration project, the project design incorporated several detection efficacy variables, such as sensitivity, specificity, and predictive value. Analyses of these outcomes were reported in several publications as the project progressed. [1][2][3][4] This report reviews the status and summary outcomes of the ACS-NPCDP. In addition, the patterns of detection and outcome in the ACS-NPCDP are compared with contemporaneous patterns of prostate cancer in the United States documented in the National Cancer Database (NCDB). BackgroundTen clinical centers recruited 2,999 healthy men age 55 to 70 years who had no history of prostate cancer, were not already under evaluation for possible C A C a n c e r J C l i n 1 9 9 7 ; 4 7 : 2 6 5 -2 7 2Vol. prostate cancer, and provided informed consent before their participation. The participants were recruited from community populations by means of public service announcements and similar promotions. Details of the protocol have been described. 1,4 Blood was drawn for PSA assessment before digital rectal examination or transrectal ultrasound was done. Real-time ultrasonography was performed in axial and sagittal projections. A suspicious outcome of digital rectal examination was defined by the presence of significant induration, nodularity, or asymmetry.If a suspicious area was defined by transrectal ultrasound or digital rectal examination, participants were requested to submit to a transrectal ultrasound-guided biopsy. When only the digital rectal examination could locate the suspicious area, a digitally guided biopsy was performed. A PSA level of more than 4.0 ng/ml was the usual indicator of the need for further evaluation.The most common exception to this guideline occurred when the transrectal ultrasound and digital rectal examination were normal and the elevation in PSA was consistent with benign gland enlargement. In these instances subjects would continue to be followed by transrectal ultrasound, digital rectal examination, and PSA assessment without immediate biopsy.Subjects who had normal biopsy outcomes continued to be monitored by transrectal ultrasound, digital rectal examination, and PSA level; they underwent biopsy again if these examinations...

show abstract

Pathology review in an early prostate cancer detection program: Results from the american cancer society‐national prostate cancer detection project

Cited by 12 publications

References 9 publications

A Reliable Biomarker Derived from Plasmalogens to Evaluate Malignancy and Metastatic Capacity of Human Cancers

A Reliable Biomarker Derived from Plasmalogens to Evaluate Malignancy and Metastatic Capacity of Human Cancers

Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

The American Cancer Society National Prostate Cancer Detection Project and National patterns of prostate cancer detection and treatment

Contact Info

Product

Resources

About